CN
Search Within
PHR1246
应用筛选条件
关键词:'PHR1246'
显示 1-30 共 103 条结果 关于 "PHR1246" 范围 论文
Adaliene Versiani Matos Ferreira et al.
Metabolism: clinical and experimental, 63(4), 456-460 (2014-01-21)
Evaluate the effect of fenofibrate treatment on the expression of PPARα and oxidative enzymes in adipose tissue. Wistar male rats were fed a balanced diet supplemented with 100mg.Kg-1 bw.day-1 fenofibrate (Sigma) during nine days. Plasma glucose, free fatty acids (FFA)
Does fenofibrate lower blood pressure?
Kwang Kon Koh
Hypertension (Dallas, Tex. : 1979), 61(3), e27-e27 (2013-01-30)
Gillian M Keating
American journal of cardiovascular drugs : drugs, devices, and other interventions, 11(4), 227-247 (2011-06-17)
Fenofibrate is a fibric acid derivative with lipid-modifying effects that are mediated by the activation of peroxisome proliferator-activated receptor-α. Fenofibrate also has a number of nonlipid, pleiotropic effects (e.g. reducing levels of fibrinogen, C-reactive protein, and various pro-inflammatory markers, and
Systemic therapies for diabetic retinopathy: the accord eye study.
Robert N Frank
Ophthalmology, 121(12), 2295-2296 (2014-12-03)
Michael S Kostapanos et al.
European journal of clinical investigation, 43(5), 522-531 (2013-03-14)
Fenofibrate has been used for the management of atherogenic dyslipidaemia for many years. Reports of fenofibrate-associated increases in serum creatinine (SCr) levels raised concerns regarding deleterious effects on renal function. In this narrative review, we discuss available literature on the
Silke Roedder et al.
PloS one, 8(2), e56657-e56657 (2013-02-26)
Despite advanced immunosuppression, redundancy in the molecular diversity of acute rejection (AR) often results in incomplete resolution of the injury response. We present a bioinformatics based approach for identification of these redundant molecular pathways in AR and a drug repositioning
Kate McKeage et al.
Drugs, 71(14), 1917-1946 (2011-09-29)
Fenofibrate is a fibric acid derivative indicated for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia in patients who have not responded to nonpharmacological therapies. The lipid-modifying effects of fenofibrate are mediated by the activation of peroxisome proliferator-activated receptor-α. Fenofibrate
Samuel Rommelaere et al.
PloS one, 9(8), e104925-e104925 (2014-08-21)
Liver is a major regulator of lipid metabolism and adaptation to fasting, a process involving PPARalpha activation. We recently showed that the Vnn1 gene is a PPARalpha target gene in liver and that release of the Vanin-1 pantetheinase in serum
Amit V Khera et al.
The American journal of cardiology, 115(2), 178-182 (2014-11-30)
Recent trials demonstrated substantial improvement in lipid parameters with inhibition of proprotein convertase subtilisin-like/kexin type 9 (PCSK9). Although statins and fibrates have been reported to increase plasma PCSK9 levels, the effect of niacin on PCSK9 is unknown. We investigated the
Nathan J Robison et al.
Pediatric blood & cancer, 61(4), 636-642 (2013-10-15)
Preclinical models show that an antiangiogenic regimen at low-dose daily (metronomic) dosing may be effective against chemotherapy-resistant tumors. We undertook a prospective, open-label, single-arm, multi-institutional phase II study to evaluate the efficacy of a "5-drug" oral regimen in children with
Yuanlong Xu et al.
Drug development and industrial pharmacy, 40(7), 972-979 (2013-05-23)
As an oral delivery carrier for poorly water soluble drugs, the nanosuspension was prepared by melt emulsification method combined with high-pressure homogenization. The objective of this study was to clarify the absorption mechanism in rats of fenofibrate nanosuspension using the
Emily Y Chew et al.
Ophthalmology, 121(12), 2443-2451 (2014-08-31)
To report additional ocular outcomes of intensive treatment of hyperglycemia, blood pressure, and dyslipidemia in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. Double 2×2 factorial, multicenter, randomized clinical trials in people with type 2 diabetes who had
Stanley M H Chan et al.
Diabetes, 62(6), 2095-2105 (2013-01-26)
Endoplasmic reticulum (ER) stress is suggested to cause hepatic insulin resistance by increasing de novo lipogenesis (DNL) and directly interfering with insulin signaling through the activation of the c-Jun N-terminal kinase (JNK) and IκB kinase (IKK) pathway. The current study
Swati Tyagi et al.
Methods in cell biology, 113, 169-187 (2013-01-16)
Single molecule Fluorescence Resonance Energy Transfer (FRET) has been widely applied to study structure, function and dynamics of complex biological systems. Labeling of proteins at specific positions with fluorescent dyes is a challenging and key step for any single molecule
Rafael Simó et al.
Reviews on recent clinical trials, 7(1), 71-80 (2011-08-26)
Diabetic retinopathy (DR) remains a leading cause of preventable vision loss, despite advances in diabetes care. The burden of DR is likely to increase as the evolving pandemic of type 2 diabetes progresses. Tight control of blood glucose levels and
Michel P Hermans
Diabetes & vascular disease research, 8(3), 180-189 (2011-05-18)
Microvascular complications are common in type 2 diabetes in primary care. Intensified management of glycaemia or blood pressure had little effect on microvascular complication rates in recent large trials (ADVANCE, VADT, ACCORD). In 2005, the FIELD study demonstrated a significant
Mark J Cziraky et al.
Journal of clinical lipidology, 7(2), 102-108 (2013-02-19)
The occurrence of low rates of rhabdomyolysis among patients receiving lipid-lowering drugs (LLDs) in randomized clinical trials may be elucidated with population-based studies. To determine the risk of hospitalized rhabdomyolysis associated with LLD therapy. This observational study used claims data
Wei Shen et al.
Biochimica et biophysica acta, 1842(7), 1109-1120 (2014-04-11)
Toll-like receptor (TLR) signaling plays a fundamental role in the induction and progression of autoimmune disease. In the present study, we showed that lipopolysaccharide (LPS), a TLR4 ligand, functions as an antagonist of peroxisome proliferator-activated receptor alpha (PPARα), a nuclear
Hywel D Williams et al.
Journal of pharmaceutical sciences, 103(8), 2441-2455 (2014-07-06)
The Lipid Formulation Classification System Consortium looks to develop standardized in vitro tests and to generate much-needed performance criteria for lipid-based formulations (LBFs). This article highlights the value of performing a second, more stressful digestion test to identify LBFs near
A D Wright et al.
Eye (London, England), 25(7), 843-849 (2011-03-26)
The approach of all ophthalmologists, diabetologists and general practitioners seeing patients with diabetic retinopathy should be that good control of blood glucose, blood pressure and plasma lipids are all essential components of modern medical management. The more recent data on
A P Agouridis et al.
Current pharmaceutical design, 16(30), 3401-3416 (2010-09-08)
We present the available data on the effects of combined therapy of fenofibrate with drugs affecting lipid metabolism other than statins. We consider studies evaluating the effects of combined therapy of fenofibrate with bile acid sequestrants (BAS), ezetimibe, niacin, n-3
Pascale Massin et al.
Ophthalmic epidemiology, 21(5), 307-317 (2014-08-19)
Fenofibrate reduced progression of diabetic retinopathy in two large randomized studies. The effect of 135 mg fenofibric acid on diabetic macular edema (DME) was evaluated in subjects with existing DME. In this double-blind, randomized, placebo-controlled study, 110 subjects with DME not
Simultaneous Estimation of Rosuvastatin Calcium and Fenofibrate in Bulk and in Tablet Dosage Form by UV-Spectrophotometry and RP-HPLC
Karunakaran A, et al.
Stamford Journal of Pharmaceutical Sciences, 4(1), 58-63 (2011)
Wen Huang et al.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 34(4), 646-653 (2014-01-16)
The strategies to protect against the disrupted blood-brain barrier (BBB) in HIV-1 infection are not well developed. Therefore, we investigated the potential of peroxisome proliferator-activated receptor (PPAR) agonists to prevent enhanced BBB permeability induced by HIV-1-specific protein Tat. Exposure to
Eli M Roth et al.
Journal of clinical lipidology, 6(6), 534-544 (2013-01-15)
Goal/desirable lipid levels are underachieved in patients with mixed dyslipidemia. These patients may have substantial residual risk of cardiovascular disease even while receiving optimal LDL-C-lowering therapy and may require additional therapy to improve multiple lipid/lipoprotein levels. To evaluate attainment of
Theodosios D Filippatos et al.
Expert opinion on pharmacotherapy, 12(12), 1945-1958 (2011-07-09)
Statin use results in a significant reduction of cardiovascular disease (CVD) risk. However, patients still have residual CVD risk, even if they are receiving optimal statin treatment. This review, based on a Pubmed/Scopus search, discusses the available evidence regarding the
Weirong Wang et al.
Experimental cell research, 319(10), 1523-1533 (2013-04-23)
The ligand-activated transcription factor peroxisome proliferator-activated receptor-α (PPARα) participates in the regulation of cellular inflammation. More recent studies indicated that sirtuin1 (SIRT1), a NAD(+)-dependent deacetylase, regulates the inflammatory response in adipocytes. However, whether the role of PPARα in inflammation is
M Masoodi et al.
Leukemia, 28(7), 1381-1387 (2014-01-15)
Oleoylethanolamide (OEA) is a bioactive lipid that stimulates nuclear and G protein-coupled receptors and regulates appetite and fat metabolism. It has not previously been shown to have a role in cancer. However, a mass spectrometry-based lipidomics platform revealed the presence
Yasemin Usul Soyoral et al.
JPMA. The Journal of the Pakistan Medical Association, 62(8), 849-851 (2013-07-19)
Rhabdomyolysis is defined as a pathological condition of skeletal muscle cell damage leading to the release of toxic intracellular components into the circulation. Several factors may lead to rhabdomyolysis. Fenofibrate is a fibric acid derivative agent that is used in
Wei He et al.
International journal of pharmaceutics, 445(1-2), 69-78 (2013-02-12)
A novel biocompatible shell-crosslinked nanocapsule system was developed based on nanoemulsion templates stabilized by a class of food proteins. The nanoemulsion templates were prepared using a combination of mechanical mixing and high-pressure homogenization, while the nanocapsule shell formed simultaneously through
1/4